IRadimed Corporation develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets under the MRidium name; and MRI compatible patient vital signs monitoring system under the IRadimed name. The company also offers IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its MRI compatible products through direct sales force and independent distributors. IRadimed Corporation was incorporated in 1992 and is headquartered in Winter Springs, Florida.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:IRMD
CUSIPN/A
Phone407-677-8022
Debt
Debt-to-Equity RatioN/A
Current Ratio8.36
Quick Ratio7.40
Price-To-Earnings
Trailing P/E Ratio352.50
Forward P/E Ratio76.22
P/E GrowthN/A
Sales & Book Value
Annual Sales$23.08 million
Price / Sales13.05
Cash Flow$0.2193 per share
Price / Cash128.57
Book Value$3.12 per share
Price / Book9.04
Profitability
EPS (Most Recent Fiscal Year)$0.08
Net Income$490,000.00
Net Margins9.57%
Return on Equity8.99%
Return on Assets7.61%
Miscellaneous
Employees83
Outstanding Shares10,680,000
Market Cap$295.84 million
Iradimed (NASDAQ:IRMD) Frequently Asked Questions
What is Iradimed's stock symbol?
Iradimed trades on the NASDAQ under the ticker symbol "IRMD."
How will Iradimed's stock buyback program work?
Iradimed announced that its Board of Directors has approved a stock repurchase program on Sunday, June 4th 2017, which authorizes the company to repurchase $8,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to buy shares of its stock through open market purchases. Shares repurchase programs are often an indication that the company's board believes its shares are undervalued.
How were Iradimed's earnings last quarter?
Iradimed Corp (NASDAQ:IRMD) posted its quarterly earnings results on Tuesday, July, 31st. The medical equipment provider reported $0.14 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.10 by $0.04. The medical equipment provider earned $7.38 million during the quarter, compared to analysts' expectations of $7.26 million. Iradimed had a return on equity of 8.99% and a net margin of 9.57%. View Iradimed's Earnings History.
When is Iradimed's next earnings date?
What price target have analysts set for IRMD?
2 analysts have issued twelve-month price objectives for Iradimed's stock. Their predictions range from $19.00 to $26.00. On average, they anticipate Iradimed's share price to reach $22.50 in the next year. This suggests that the stock has a possible downside of 20.2%. View Analyst Price Targets for Iradimed.
What is the consensus analysts' recommendation for Iradimed?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iradimed in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Iradimed.
Who are some of Iradimed's key competitors?
Some companies that are related to Iradimed include Atrion (ATRI), AtriCure (ATRC), Tactile Systems Technology (TCMD), OraSure Technologies (OSUR), Orthofix International (OFIX), Cerus (CERS), SurModics (SRDX), K2M Group (KTWO), Intersect ENT (XENT), AngioDynamics (ANGO), LeMaitre Vascular (LMAT), Anika Therapeutics (ANIK), Neuronetics (STIM), MiMedx Group (MDXG) and Antares Pharma (ATRS).
Who are Iradimed's key executives?
Iradimed's management team includes the folowing people:
- Mr. Roger E. Susi, Founder, Chairman, CEO & Pres (Age 65)
- Mr. Christopher K. Scott, CFO & Sec. (Age 48)
- Mr. John McCreery, Chief Operating Officer (Age 63)
- Mr. Brent Johnson, Exec. VP of Worldwide Sales & Marketing (Age 59)
- Mr. Louis Waldman, Controller (Age 63)
Has Iradimed been receiving favorable news coverage?
Press coverage about IRMD stock has been trending somewhat positive this week, according to Accern Sentiment. Accern rates the sentiment of news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Iradimed earned a coverage optimism score of 0.16 on Accern's scale. They also assigned news coverage about the medical equipment provider an impact score of 45.56 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next few days. View Recent Headlines for Iradimed.
Who are Iradimed's major shareholders?
Iradimed's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (2.15%), Mondrian Investment Partners LTD (1.58%), Cadence Capital Management LLC (1.35%), Renaissance Technologies LLC (1.10%), Russell Investments Group Ltd. (0.83%) and Boston Partners (0.59%). Company insiders that own Iradimed stock include Christopher K Scott, Francis X Casey, John K Mccreery, Louis S Waldman, Monty K Allen, Roger E Susi and Steven M Nardi. View Institutional Ownership Trends for Iradimed.
Which institutional investors are selling Iradimed stock?
IRMD stock was sold by a variety of institutional investors in the last quarter, including Mondrian Investment Partners LTD and Boston Partners. Company insiders that have sold Iradimed company stock in the last year include Christopher K Scott, Francis X Casey, John K Mccreery, Louis S Waldman, Monty K Allen and Steven M Nardi. View Insider Buying and Selling for Iradimed.
Which institutional investors are buying Iradimed stock?
IRMD stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Renaissance Technologies LLC, Cadence Capital Management LLC, Russell Investments Group Ltd., Bank of America Corp DE, EAM Investors LLC and Bank of New York Mellon Corp. View Insider Buying and Selling for Iradimed.
How do I buy shares of Iradimed?
Shares of IRMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Iradimed's stock price today?
One share of IRMD stock can currently be purchased for approximately $28.20.
How big of a company is Iradimed?
Iradimed has a market capitalization of $295.84 million and generates $23.08 million in revenue each year. The medical equipment provider earns $490,000.00 in net income (profit) each year or $0.08 on an earnings per share basis. Iradimed employs 83 workers across the globe.
How can I contact Iradimed?
Iradimed's mailing address is 1025 Willa Springs Dr., Winter Springs FL, 32708. The medical equipment provider can be reached via phone at 407-677-8022 or via email at [email protected]
MarketBeat Community Rating for Iradimed (NASDAQ IRMD)
MarketBeat's community ratings are surveys of what our community members think about Iradimed and other stocks. Vote "Outperform" if you believe IRMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IRMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
